Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luvira Viravarn, Schilling William H K, Jittamala Podjanee, Watson James A, Boyd Simon, Siripoon Tanaya, Ngamprasertchai Thundon, Almeida Pedro J, Ekkapongpisit Maneerat, Cruz Cintia, Callery James J, Singh Shivani, Tuntipaiboontana Runch, Kruabkontho Varaporn, Ngernseng Thatsanun, Tubprasert Jaruwan, Abdad Mohammad Yazid, Keayarsa Srisuda, Madmanee Wanassanan, Aguiar Renato S, Santos Franciele M, Hanboonkunupakarn Pongtorn, Hanboonkunupakarn Borimas, Poovorawan Kittiyod, Imwong Mallika, Taylor Walter R J, Chotivanich Vasin, Chotivanich Kesinee, Pukrittayakamee Sasithon, Dondorp Arjen M, Day Nicholas P J, Teixeira Mauro M, Piyaphanee Watcharapong, Phumratanaprapin Weerapong, White Nicholas J, PLATCOV Collaborative Group
Аннотация
BACKGROUND: Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries.
METHODS: In a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with early symptomatic COVID-19 were randomised to one of ten treatment arms including high dose oral favipiravir (3.6g on day 0 followed by 1.6g daily to complete 7 days treatment) or no study drug. The primary outcome was the rate of viral clearance (derived under a linear mixed-effects model from the daily log10 viral densities in standardised duplicate oropharyngeal swab eluates taken daily over 8 days [18 swabs per patient]), assessed in a modified intention-to-treat population (mITT). The safety population included all patients who received at least one dose of the allocated intervention. This ongoing adaptive platform trial was registered at ClinicalTrials.gov (NCT05041907) on 13/09/2021.
RESULTS: In the final analysis, the mITT population contained data from 114 patients randomised to favipiravir and 126 patients randomised concurrently to no study drug. Under the linear mixed-effects model fitted to all oropharyngeal viral density estimates in the first 8 days from randomisation (4,318 swabs), there was no difference in the rate of viral clearance between patients given favipiravir and patients receiving no study drug; a -1% (95% credible interval: -14 to 14%) difference. High dose favipiravir was well-tolerated.
INTERPRETATION: Favipiravir does not accelerate viral clearance in early symptomatic COVID-19. The viral clearance rate estimated from quantitative measurements of oropharyngeal eluate viral densities assesses the antiviral efficacy of drugs in vivo with comparatively few studied patients.